Ipilimumab

• Catalog Number: orb1290249
• Category: Antibodies
• Description: Ipilimumab biosimilar antibody
• Target: CTLA4/CD152
• Clonality: Monoclonal
• Species/Host: Mouse
• Isotype: IgG1-kappa
• Conjugation: Unconjugated
• Reactivity: Human
• Buffer/Preservatives: PBS buffer pH 7.5
• Purity: > 95%
• Tested applications: ELISA
• Antibody Type: Biosimilar Antibody
• Source: CHO cells
• Biological Activity: Ipilimumab (anti-CTLA-4), is a fully humanized IgG1k monoclonal antibody produced by recombinant DNA technology in a CHO mammalian cell expression system, binding with high affinity to the extracellular domain of human (and Cynomolgus monkey) CTLA-4, and acting as an inhibitor of its complex functions. This essentially results in T-cell activation and proliferation, and in lymphocyte infiltration leading to tumor cell death. However, the enhancement of T effector cell function, combined with the inhibition of CD4+ Treg and CD8+ suppressive cell types, are considered essential for mediating the full therapeutic effects of ipilimumab. Ipilimumab can improve ATC proliferation, enhance the BiAb-mediated tumor-specific cytotoxicity, and increase cytokine synthesis, while it attenuates Treg activity as shown by decreased level of IL-10 secretion and reduced Treg population. Ipilimumab and nivolumab treatments could collaboratively enhance effector and memory T cell responses without inappropriately activating naive T cells.
• CAS Number: 477202-00-9
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Alternative names: BMS-734016, MDX-010, MDX-CTLA-4
• Note: For research use only